Last updated: June 7, 2026
Litigation Summary and Analysis for Gilead Sciences, Inc. v. Lupin Limited (1:23-cv-00508): What Patents Are at Issue, What the Case History Shows, and What Generic-Entry Risks Exist
Gilead Sciences, Inc. v. Lupin Limited (U.S. District Court, Case No. 1:23-cv-00508) is a Hatch-Waxman patent infringement action tied to Lupin’s FDA Abbreviated New Drug Application (ANDA) for a Gilead brand product. The litigation posture, key docket events, and infringement theories are not determinable from the information provided. Without the court docket content (complaint, exhibits, answers, scheduling order, claim construction, Markman order, any summary judgment, and any stay/settlement filings), a complete and accurate patent-and-timeline analysis cannot be produced.
What patents does Gilead allege Lupin infringes in 1:23-cv-00508?
A precise patent list and asserted claims cannot be extracted because the operative pleadings and exhibits are not included in the input. Without the complaint’s infringement count, identification of Orange Book listed patents, and any exhibit containing the specific asserted claims, any “what patents are at issue” summary would be incomplete.
Which Orange Book listed patents are typically asserted in this Gilead v. Lupin fact pattern?
For Hatch-Waxman cases, asserted patents generally fall into one or more buckets: composition-of-matter, formulation (including crystalline form/polymorph or salts), method-of-use, and sometimes manufacturing/process. The exact patents and the asserted claim numbers for this docket are not present.
How has the case progressed in 1:23-cv-00508 (docket events and key procedural milestones)?
A procedural and outcomes summary requires docket-level facts such as:
- complaint filing date and venue assignment
- answer and counterclaims timing
- Rule 26 scheduling order
- infringement contentions and invalidity contentions
- claim construction schedule (Markman)
- summary judgment or Daubert rulings
- trial date and dispositive motion outcomes
- any stipulations (dismissal without prejudice, partial judgment on noninfringement/invalidity)
- any settlement-triggered stay or consent judgment
None of these docket events are provided, so a timeline cannot be stated accurately.
Has the litigation been stayed pending PTO proceedings or settlement?
Stay/abatement can occur via:
- stipulation pending post-grant review or reexamination
- appellate or claim construction stay
- settlement and dismissal
The existence and terms of any stay are not available from the input.
What is the infringement theory in Gilead v. Lupin (method-of-use vs. composition vs. formulation)?
A claim-by-claim infringement analysis requires:
- identification of the asserted independent and dependent claims
- the ANDA product description in the complaint (HATCH-WAXMAN paragraph references)
- Lupin’s certification and paragraph basis (Paragraph I, II, III, IV)
- the court’s construction of claim terms (if any)
None of this content is included, so infringement theory cannot be reported.
When does exclusivity end, and when could a generic launch occur if Lupin wins 1:23-cv-00508?
Launch timing depends on multiple layers:
- patent expiration dates for the specific asserted Orange Book patents
- any listed regulatory exclusivities (NCE, data exclusivity, orphan exclusivity)
- pediatric exclusivity extensions, if applicable
- FDA approval and marketing exclusivity status
Because the asserted patents and their expiration dates are not specified, launch risk and exclusivity timelines cannot be calculated.
What Paragraph IV certifications did Lupin submit, and how do they affect risk?
Hatch-Waxman risk hinges on whether Lupin certified:
- Paragraph II (patent expired)
- Paragraph III (waiting for expiration)
- Paragraph IV (patent not infringed/invalid)
The ANDA certification basis for this docket is not provided.
What remedies does Gilead seek (injunction, damages, fees), and what remedies are available?
A remedies analysis requires the complaint’s prayer for relief and any later orders on injunction scope. In Hatch-Waxman cases, plaintiffs often seek:
- 35 U.S.C. § 271(e)(2) infringement remedies for ANDA activities
- a permanent injunction under 35 U.S.C. § 283 and relevant Hatch-Waxman standards
- damages
- attorneys’ fees under 35 U.S.C. § 285 (if the case progresses to willfulness)
Those specifics are not included, so remedies cannot be summarized accurately.
How strong is Gilead’s patent estate for this product as asserted in 1:23-cv-00508?
A strength assessment requires:
- the asserted claim set
- priority dates, prosecution history (for estoppel), and maintenance status
- litigated validity positions and any prior art discussed
- claim construction outcomes
- any PTO activity that affects enforceability
Without the asserted patents and their claim details, an evidence-based strength analysis cannot be produced.
Which other companies are likely co-litigants or at risk in the same Gilead product category?
Risk mapping requires the Orange Book patent family, listing holders, and which generic applicants filed ANDAs with certifications. None of that listing context is provided.
What generic entry risks exist for Lupin if Gilead loses or settles 1:23-cv-00508?
Entry risk depends on:
- whether the case results in final noninfringement or invalidity findings for the asserted patents
- whether any remaining unasserted patents would still block approval
- whether FDA approval has already been granted, whether a 30-month stay is in effect, and whether that stay has been lifted
None of these facts are in the input, so the generic-entry risk cannot be quantified.
How do settlement patterns typically change Hatch-Waxman outcomes (and what is relevant here)?
Settlement can lead to:
- dismissal with prejudice
- consent judgment
- covenant not to sue as to specific patents
- entry dates and design-around commitments
- licensing agreements
The presence, terms, or absence of any settlement in 1:23-cv-00508 are not provided.
What is the regulatory status of the ANDA at issue in 1:23-cv-00508?
A regulatory status summary requires:
- FDA approval date (if approved)
- tentative approval status
- whether the applicant launched “at risk” outside the stay
- labeling details and bioequivalence study results
These are not included, so regulatory status cannot be stated.
What court outcomes matter most for future enforcement against Lupin (and other generics)?
Outcome categories that matter:
- final judgments on infringement and validity
- claim construction that may apply to future cases
- rulings on inequitable conduct, laches, or prosecution laches
- stay and injunction status
These require docket-specific rulings, which are not included.
Key Takeaways
- A litigation summary and patent-by-patent infringement and validity analysis for Gilead Sciences, Inc. v. Lupin Limited (1:23-cv-00508) cannot be completed from the provided information because the asserted patents, claim details, ANDA certification basis, and docket milestones are not supplied.
- A credible generic-entry and exclusivity risk assessment also cannot be calculated without the specific Orange Book patents at issue and their expiration dates.
- A procedural and remedies analysis requires docket filings (complaint, answer, scheduling orders, and any claim construction and dispositive orders).
FAQs
- What patents are typically asserted in Gilead Hatch-Waxman cases like 1:23-cv-00508?
- Does a Paragraph IV filing always trigger a 30-month stay, and when can it be lifted?
- How do claim construction outcomes usually affect infringement and invalidity in ANDA patent suits?
- What settlement structures are common in Gilead generic litigation, and how do they map to entry dates?
- How can PTO inter partes review or other post-grant proceedings change the litigation risk profile?
References
No sources were provided in the input to cite.
